BODENSTEDT MATTHIAS (Chief Financial Officer) sold 1.5% of their position (17.88K shares) of MOONLAKE IMMUNOTHERAPEUTICS on the open market
Open‑market sale worth $351.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 6/18/2026ACC: 0001213900-26-070259
Officer· Chief Financial Officer
Since Apr 2022
-17.88K
Net shares
Net seller
$351.6K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
17.88K disposed
Non-Derivative Transactions2
Class A ordinary shares, par value $0.0001 per share
Direct
Shares
−15.08K
Price / share
$19.68
Trade value
$296.81K
% of position
1.3%
6/17/2026
1.17M→1.16M
Class A ordinary shares, par value $0.0001 per share
Direct
Shares
−2.79K
Price / share
$19.60
Trade value
$54.76K
% of position
0.2%
6/18/2026
1.16M→1.15M
Total
Net shares
−17.88K
Net value
-$351.58K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per share Direct | 6/17/2026 | S · Sale | −15.08K | $19.68 | $296.81K | 1.3% | 1.17M | 1.16M |
| Class A ordinary shares, par value $0.0001 per share Direct | 6/18/2026 | S · Sale | −2.79K | $19.60 | $54.76K | 0.2% | 1.16M | 1.15M |
| Total | −17.88K | -$351.58K | ||||||
Derivative Transactions0
No derivative transactions reported